Global Lithium finds a faster path to Manna lithium production through Nova

Global Lithium’s Manna-Nova integration study nearly doubles the project’s post-tax NPV to A$945.7 million while cutting funded pre-production capital by 59%. The plan targets first direct shipping ore in May 2027 and spodumene concentrate production by mid-2027, but still depends on funding, approvals and a final investment decision.

  • Post-tax NPV rises to A$945.7 million from A$472.4 million
  • Funded pre-production capital falls to A$180.1 million
  • First DSO shipment targeted for May 2027
  • Probable Ore Reserve increases 8% to 20.9Mt
  • FID remains targeted for the December quarter of 2026
An image related to Global Lithium Resources Limited
Image © middle. Logo © respective owner.

Nova conversion reshapes Manna economics

Global Lithium Resources Limited (ASX:GL1) has turned its proposed acquisition of IGO’s Nova processing facility into a sharp repricing of the Manna lithium project, with the integration study lifting post-tax NPV8 to A$945.7 million from A$472.4 million in the December 2025 feasibility study.

The central change is straightforward: instead of building a greenfield concentrator at Manna, ore will be hauled 135 kilometres to Nova and processed through a modified 1.8Mtpa flotation plant. Existing crushing, milling and flotation infrastructure will be retained, with ore sorting, magnetic separation, desliming and a brine pond added for lithium duty.

That redesign cuts funded pre-production capital to A$180.1 million from A$439.1 million, while peak funding falls to A$177.3 million from A$478.3 million. The project’s modelled payback period also contracts to 0.9 years from production start, compared with 3.5 years under the standalone Manna DFS.

Early DSO revenue brings forward the cash cycle

Global Lithium plans to use the crushing and ore-sorting circuit to produce direct shipping ore before the converted wet plant is fully operational. DSO production is targeted to begin in March 2027, with the first shipment scheduled for May and approximately 336,944 tonnes planned for export during the campaign.

First SC5.5 spodumene concentrate is targeted for mid-2027, with the wet plant expected to reach steady state in February 2028. The integrated plan forecasts 2.684 million tonnes of concentrate over a 13-year producing life, including average annual output of 257,000 tonnes of SC5.5 during the first seven years.

The project’s headline return metrics are correspondingly dramatic: post-tax IRR rises to 119.6%, or about 120%, from 25.7%, while the value-to-funded-capital ratio increases to 5.25 times from 1.08 times. Those figures remain study outputs rather than operating results, and the company has not yet made the final investment decision.

Reserve grows, but production still includes inferred material

Manna’s Probable Ore Reserve rises 8% to 20.96 million tonnes at 0.89% Li2O, comprising 14.7Mt from the open pit and 6.2Mt underground. The reserve is entirely supported by Indicated Mineral Resources, although the broader 23.67Mt production inventory includes 2.72Mt of Inferred material.

That distinction matters. Global Lithium says the production target is underpinned by about 88% Probable Ore Reserve and roughly 11% to 12% Inferred Resources. The company cautions that the lower geological confidence attached to Inferred material means there is no certainty it will convert to Indicated Resources or contribute to the planned production profile.

Price assumptions support the valuation uplift

The increase in project value is not solely the result of lower capital. The integration study uses a different financial basis from the DFS, including a 0.69 AUD/USD exchange rate and a weighted average life-of-mine SC5.5 price of US$1,510 per tonne. The DFS used a flat long-term US$1,400 per tonne SC6 price and a 0.67 exchange rate.

Global Lithium’s sensitivity analysis identifies spodumene pricing and foreign exchange as the dominant drivers of NPV. A 20% increase in revenue pricing takes post-tax NPV to about A$1.6 billion, while a 20% decline reduces it to roughly A$0.5 billion. Operating costs also rise: C1 cash cost increases to A$1,042.2 per tonne of concentrate from A$964.6, largely reflecting the new Manna-to-Nova haulage chain.

The company says no additional metallurgical testwork was conducted for the integration study. Recovery remains modelled at 72.85%, matching the DFS, while the study is a Class 3 estimate with approximately plus or minus 20% accuracy. Those qualifications place a useful boundary around the headline valuation.

Funding and execution gates remain ahead

Seventy percent of planned concentrate production is covered by existing offtake arrangements with Lopal and Canmax. Lopal’s binding term sheet also provides for up to US$75 million of concentrate prepayment funding at 5% annual interest, subject to a positive FID and definitive documentation. Global Lithium has separately flagged potential DSO prepayment, further funding discussions and proceeds from the proposed Marble Bar divestment.

None of that removes the financing gap entirely. The company states that additional funding may be required, that availability and terms are not guaranteed, and that equity funding could dilute existing shareholders. The Nova acquisition itself, plant conversion, logistics arrangements and remaining approvals must also align with the schedule.

FID is targeted for the December quarter of 2026, followed by pre-strip mining and sorter commissioning in March 2027. The most immediate test is whether Global Lithium can convert a highly favourable study model into binding funding, completed asset transfer and a functioning ore-sorting circuit quickly enough to preserve the May 2027 first-shipment target.

Bottom Line?

The Nova strategy has materially improved Manna’s modelled economics, but the investment case now rests on execution: funding, asset transfer, approvals and plant conversion must all arrive before the valuation can be tested in the field.

Questions in the middle?

  • Can Global Lithium secure the full A$180.1 million funding requirement without material equity dilution?
  • Will the converted Nova plant achieve the study’s 72.85% recovery and planned throughput during ramp-up?
  • Can the company complete the Nova transaction, approvals and logistics arrangements in time for first DSO shipment in May 2027?